You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Gilead Sciences's competition from AbbVie and Merck is just one of the reasons.
After a solid two-year run, Gilead Sciences (GILD 0.84%) has fallen from investors graces, down for the year. The biotech has become increasingly reliant on its hepatitis C drug Sovaldi, with competition from AbbVie (ABBV 3.31%)and Merck (MRK 1.51%) around the corner.
In the slideshow below, you'll find three reasons investors are down on Gilead Sciences and thoughts on the biotech's future.
Dr. Orelli is a Senior Biotech Specialist. He has written about biotech, pharmaceutical, and medical device companies for The Motley Fool since 2007.
Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
